GSK plc confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court. This case was set to go to trial on February 20, and instead will now be dismissed. “The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- GSK Boosts Outlook Backed by Solid Drug Pipeline
- Options Volatility and Implied Earnings Moves Today, January 31, 2024
- GSK reports Q4 adjusted EPS 28.9p, consensus 29.9p
- Lixte Biotechnology announces first patient dosed in Phase 1b/2 trial of LB-100
- GSK RSV vaccine accepted for regulatory review by EMA for adults 50-59
